Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Cited In for PubMed (Select 16842444)

1.

A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014.

Wen Y, Zheng YX, Tan de M.

Hepat Mon. 2015 May 23;15(5):e27181. doi: 10.5812/hepatmon.15(5)2015.27181. eCollection 2015 May. Review.

2.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15:156. doi: 10.1186/s12879-015-0888-x.

3.

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Smith-Palmer J, Cerri K, Valentine W.

BMC Infect Dis. 2015 Jan 17;15:19. doi: 10.1186/s12879-015-0748-8.

4.

KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver (KASL).

Clin Mol Hepatol. 2014 Jun;20(2):89-136. doi: 10.3350/cmh.2014.20.2.89. Epub 2014 Jun 30. No abstract available.

5.

Molecular mechanism and treatment of viral hepatitis-related liver fibrosis.

Su TH, Kao JH, Liu CJ.

Int J Mol Sci. 2014 Jun 12;15(6):10578-604. doi: 10.3390/ijms150610578. Review.

6.

Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C.

Hung CH, Chiu YC, Hu TH, Chen CH, Lu SN, Huang CM, Wang JH, Lee CM.

Transl Oncol. 2014 Aug;7(4):503-7. doi: 10.1016/j.tranon.2014.05.001. Epub 2014 Jun 2.

7.

Direct-acting antiviral agents in patients with hepatitis C cirrhosis.

Im GY, Dieterich DT.

Gastroenterol Hepatol (N Y). 2012 Nov;8(11):727-65.

8.

Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Toshikuni N, Arisawa T, Tsutsumi M.

World J Gastroenterol. 2014 Mar 21;20(11):2876-87. doi: 10.3748/wjg.v20.i11.2876. Review.

9.

Reasons for Nonattendance across the Hepatitis C Disease Course.

Butt G, McGuinness L, Buller-Taylor T, Mitchell S.

ISRN Nurs. 2013 Sep 11;2013:579529. doi: 10.1155/2013/579529. eCollection 2013.

10.

Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.

Hsu CS, Huang CJ, Kao JH, Lin HH, Chao YC, Fan YC, Tsai PS.

PLoS One. 2013 Jul 23;8(7):e70458. doi: 10.1371/journal.pone.0070458. Print 2013.

11.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

12.

Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy.

Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH.

Aliment Pharmacol Ther. 2013 May;37(9):887-94. doi: 10.1111/apt.12273. Epub 2013 Mar 6.

13.

Effects and outcomes of interferon treatment in Japanese hepatitis C patients.

Yamasaki K, Tomohiro M, Nagao Y, Sata M, Shimoda T, Hirase K, Shirahama S.

BMC Gastroenterol. 2012 Oct 12;12:139. doi: 10.1186/1471-230X-12-139.

14.

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.

D'Ambrosio R, Aghemo A.

Hepat Mon. 2012 Jun;12(6):361-8. doi: 10.5812/hepatmon.6095. Epub 2012 Jun 30.

15.

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.

Choi SB, Lee YJ, Lee JI, Song YJ, Choi BJ, Kim JH, Jung EU, Park SJ, Lee SH, Kim JH, Choi JS, Jee SR, Seol SY.

Korean J Hepatol. 2011 Sep;17(3):183-8. doi: 10.3350/kjhep.2011.17.3.183.

16.

Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma.

Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC.

Gut Liver. 2011 Mar;5(1):77-81. doi: 10.5009/gnl.2011.5.1.77. Epub 2011 Mar 16.

17.

Hepatitis C in haematological patients.

Hwang YY, Liang RH.

Hepat Res Treat. 2010;2010:961359. doi: 10.1155/2010/961359. Epub 2010 Aug 25.

18.

Hepatocellular carcinoma in Hepatitis C genotype 4 after viral clearance and in absence of cirrhosis: two case reports.

Derbala M, Amer A.

Cases J. 2009 Sep 15;2:7927. doi: 10.1186/1757-1626-0002-0000007927.

19.

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.

Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC.

World J Gastroenterol. 2007 Nov 14;13(42):5648-53.

20.

Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease.

Trinchet JC, Ganne-CarriƩ N, Nahon P, N'kontchou G, Beaugrand M.

World J Gastroenterol. 2007 May 7;13(17):2455-60. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk